Business Context and Reporting Period
Company: Mesoblast Limited (Mesoblast)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Nine months ended March 31, 2020
Business Overview: Mesoblast is a clinical-stage biotechnology company developing allogeneic cellular medicines based on mesenchymal lineage adult stem cells. Key product candidates include RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (SR-aGVHD), REVASCOR for advanced heart failure, and MPC-06-ID for chronic low back pain. The company relies on strategic partnerships and licensing agreements for revenue, as it has not yet generated significant revenue from product sales.
Key Financial Metrics
| Metric (in thousands USD) | 9 Months Ended Mar 31, 2020 | 9 Months Ended Mar 31, 2019 |
|---|---|---|
| Total Revenue | $31,455 | $14,755 |
| Net Loss | $(45,330) | $(69,073) |
| Loss Per Share (Basic & Diluted) | $(0.0866) | $(0.1402) |
| Operating Cash Flow | $(36,783) | $(38,704) |
| Cash and Cash Equivalents (End of Period) | $60,077 | $70,385 |
| Total Debt (Borrowings) | $86,951 | $81,286 |
| Net Debt | $(35,695) | $(30,860) |
Note: Revenue includes significant non-recurring milestone payments. Operating expenses remain high due to clinical trial costs and manufacturing development.
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased 113% to $31.5 million, driven primarily by $25.0 million in milestone revenue. This includes a $15.0 million upfront fee from a new strategic partnership with Grünenthal and the recognition of the remaining $10.0 million from a prior Tasly agreement.
- Reduced Net Loss: The net loss decreased by 34% to $45.3 million, largely due to the revenue spike and a $1.3 million gain from the remeasurement of contingent consideration (compared to a $3.3 million loss in the prior year).
- Expense Trends:
- R&D Expenses: Decreased 15% to $40.9 million, primarily due to reduced third-party costs as Phase 3 trial enrollments for key candidates were completed.
- Manufacturing Commercialization: Increased 20% to $15.5 million, reflecting stock build-up for the potential launch of RYONCIL.
- Finance Costs: Increased 25% to $9.9 million due to higher interest expenses on existing debt facilities.
- Debt Structure: Total borrowings increased to $87.0 million. A portion of the Hercules loan ($20.5 million) was classified as current at period-end because deferral requirements were not yet met, though this was resolved subsequently.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management anticipates continuing to incur significant losses for the foreseeable future. Capital requirements are expected to increase as the company moves toward commercialization, specifically for scaling manufacturing and establishing sales infrastructure. The company expects R&D expenses to decrease in the short term as Phase 3 trials conclude, but total expenses will rise upon regulatory approval.
Going Concern Uncertainty
The filing explicitly states a material uncertainty regarding the company's ability to continue as a going concern. Viability depends on meeting milestones under the Grünenthal and NovaQuest agreements, drawing down remaining funds from the Hercules facility, or securing additional equity financing.
Key Risks and Contingencies
- Regulatory Approval: The FDA has accepted the Biologics License Application (BLA) for RYONCIL for priority review with an action date of September 30, 2020. Approval is not guaranteed.
- COVID-19 Impact: The pandemic poses risks to clinical trial enrollment, manufacturing continuity (specifically at the Lonza Singapore facility), and the FDA inspection process.
- Debt Covenants: Loan facilities with Hercules and NovaQuest contain restrictive covenants. Failure to meet these could result in acceleration of debt repayment.
- Manufacturing Reliance: The company relies entirely on Lonza for manufacturing. Any disruption at Lonza's facilities could halt development and commercialization.
Subsequent Events
On May 13, 2020, Mesoblast successfully raised $90.0 million (A$138.0 million) through a share placement. Additionally, the company satisfied requirements to defer principal repayments on its Hercules borrowings to October 2020.
Investor Verification Checklist
- Capital Runway: Verify the impact of the $90 million May 2020 capital raise on the company's cash runway and ability to fund operations through 2021.
- R&YONCIL Approval Timeline: Monitor the FDA's decision on the RYONCIL BLA by the September 30, 2020 PDUFA date, as this is the primary catalyst for future revenue.
- Debt Deferral Status: Confirm that the deferral of Hercules principal repayments to October 2020 (and potentially July 2021) remains in effect and that covenants are being met.
- Manufacturing Capacity: Assess the status of Lonza's Singapore facility regarding COVID-19 disruptions and its ability to scale production for commercial launch.
- Milestone Revenue Sustainability: Evaluate the likelihood of achieving future milestones under the Grünenthal partnership, as current revenue is heavily weighted by one-time upfront fees.